Elevation Oncology, Inc. (ELEV)

4.3000 +0.2500 (+6.17%) As of 03:44PM EDT. Market open.

Elevation Oncology, Inc.

101 Federal Street
Suite 1900
Boston, MA 02110
United States
716 371 1125
https://elevationoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 29

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David Dornan Ph.D.	Chief Scientific Officer	545.5k	N/A	1978
Ms. Valerie Malyvanh Jansen M.D., Ph.D.	Chief Medical Officer	641.53k	N/A	1978
Mr. Joseph J. Ferra Jr.	CEO, President & Director	391.52k	N/A	1975
Ms. Tammy Furlong CPA, P.M.P.	CFO & Secretary	N/A	N/A	N/A
Mr. Ryan Bloomer	Head of Tech Ops	N/A	N/A	N/A
Candice Masse	Senior Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Robert C. Yang	Vice President of Legal Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Corporate governance

Elevation Oncology, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.